GENOME EDITING 111
Fig. 2. Making specific changes in DNA has been much simplified with CRISPR.
technology nearly 10 years ago, we have great expertise in this area. Tis experience is especially important when it comes to crafting genome editing tools that possess the critical requirements of having specific targeting and robust cutting activity,” notes the company.
Pre-designed CRISPR sites that minimise off-targeting are available for coding regions of the human, mouse, and rat genomes. Custom designs for any other regions or species are always available upon request, says the company.
Its CRISPR paired nickases minimise off-target double- stranded breaks by requiring the independent binding of two separate gRNAs to a localised genomic region. In the presence of the Cas9-D10A nicking nuclease, the two gRNAs induce single-stranded breaks on opposite strands of the DNA, creating a functional double- stranded break.
When ordering CRISPR paired nickases for a specific target, researchers will receive ready-to- use, transfection-grade plasmids expressing gRNA from the human U6 promoter.
OriGene’s latest contribution to the market is its new genome- wide gene-knockout kits using the CRISPR platform. Te gene- centric research tool supplier’s new product line provides a complete solution for researchers to knock out a human gene at the chromosomal level. Tis, says the company, provides unprecedented convenience for genome editing using the CRISPR technology.
“CRISPR is an innovative tool for biomedical scientists. Our dream of a pair of simple accurate molecular scissor is now a reality. Launching
genome-wide knock-out kits is only the very first step for OriGene to help harness the power of the CRISPR technology,” said Dr Wei-Wu He, CEO and chairman of OriGene.
“OriGene is in a perfect position to provide genome wide CRISPR tools to the research community. We provide a kit against every human gene locus, containing two gRNAs and a compatible donor vector with a functional cassette,” added Dr Youmin Shu, senior vice president of molecular biology with the company.
Clontech licenses CRISPR/Cas9 technology from the Broad Institute C
lontech Laboratories, a wholly owned subsidiary of Takara Bio, has entered into a non-exclusive licence agreement with
the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. “Clontech is pleased to be able to provide innovative
tools for CRISPR/Cas9 gene editing under our Guide-it brand,” commented general manager Carol Lou. “We believe that CRISPR/Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use. It is destined to become as
valuable and widely utilised as RNAi; perhaps more so.” Clontech’s initial product offering includes Guide-it
kits for in vitro production and screening of single guide RNAs (sgRNAs) and a method to confirm the presence of targeted mutations using direct PCR and Clontech’s own Guide-it Resolvase enzyme. The company develops, manufactures and
distributes a wide range of life science research agents under both the Clontech and Takara brands. Key products include SMARTer cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including
the TaKaRa Ex Taq, TaKaRa LA Taq, Titanium, and Advantage enzymes); RT enzymes and SMART library construction kits; the In-Fusion cloning system; tet- based inducible gene expression systems; Living Colours fluorescent proteins; and a range of Macherey-Nagel nucleic acid purification tools. Launched in 2004, the Broad Institute is dedicated
to discovering the molecular basis of major human diseases, developing effective new approaches to diagnostics and therapeutics, and disseminating discoveries, tools, methods, and data openly to the entire scientific community.
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120